Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Operating Leases (2021 - 2025)

Capricor Therapeutics (CAPR) has 5 years of Operating Leases data on record, last reported at $14.4 million in Q3 2025.

  • For Q3 2025, Operating Leases rose 1627.5% year-over-year to $14.4 million; the TTM value through Sep 2025 reached $14.4 million, up 1627.5%, while the annual FY2024 figure was $616315.0, 58.55% down from the prior year.
  • Operating Leases reached $14.4 million in Q3 2025 per CAPR's latest filing, up from $194603.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $14.4 million in Q3 2025 and bottomed at $194603.0 in Q2 2025.
  • Average Operating Leases over 5 years is $2.3 million, with a median of $1.6 million recorded in 2023.
  • The widest YoY moves for Operating Leases: up 1627.5% in 2025, down 81.36% in 2025.
  • A 5-year view of Operating Leases shows it stood at $2.5 million in 2021, then fell by 23.43% to $1.9 million in 2022, then fell by 20.83% to $1.5 million in 2023, then tumbled by 58.55% to $616315.0 in 2024, then skyrocketed by 2240.15% to $14.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $14.4 million in Q3 2025, $194603.0 in Q2 2025, and $407392.0 in Q1 2025.